A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression

  • End date
    Jan 14, 2026
  • participants needed
  • sponsor
    Fudan University
Updated on 14 March 2022
Accepts healthy volunteers


Zanubrutinib is a highly specific, potent new Bruton's tyrosine kinase (BTK) inhibitor, with minimal off-target inhibition of other kinases. This is a single-arm, open-label Phase II study to evaluate the efficacy and safety of zanubrutinib in combination with Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in newly diagnosed non-GCB Diffuse large B-cell lymphoma (DLBCL) patients with co-expression of B-cell lymphoma 2 (BCL2)and myelocytomatosis oncogene(MYC).


Diffuse large B-cell lymphoma as the most common lymphoma, is heterogeneous. R-CHOP is the standard care in front-line DLBCL treatment. However, there are still about 40% of the DLBCL patients treated with R-CHOP relapse or respond poorly.

There are 20%-30% DLBCL patients having BCL2 and MYC co-expression, which are more common in activated B -cell-like(ABC)-DLBCL. Previous study showed that patients with co-expression of BCL2 and MYC by immunohistochemistry (IHC) have a worse outcome with R-CHOP.

Efficacy results from Studies PCYC-04753 and PCYC-1106-CA demonstrate that BTK inhibitor ibrutinib has some activity as a single agent in subjects with relapsed or refractory DLBCL, with possible lower response rates in subjects with the germinal center B-cell-like (GCB)subtype.

In post hoc of PHEONIX study, non-GCB subgroup pts with MYC-high + BCL2-high had better event free survival (EFS )(HR 0.648; 95% confidence interval (CI), 0.423-0.993; p = 0.045) with ibrutinib + R-CHOP versus placebo + R-CHOP.

Zanubrutinib is a highly specific, potent new BTK inhibitor, with minimal off-target inhibition of other kinases, and is associated with better tolerability, compared with ibrutinib. A post hoc analysis on 4 studies found that Patients with MYC and BCL2 double-expressor DLBCL resulted in objective response rate(ORR)of 61% and progression free survival (PFS) of 5.4m when treated with zanubrutinib. However, it is still unknown the benefit of zanubrutinib and RCHOP combination therapy followed by zanubrutinib maintenance in non-GCB DLBCL patients with co-expression of BCL2 and MYC.

This is a single-arm, phase II study, to evaluate the efficacy and safety of zanubrutinib in combination with R-CHOP followed by zanubrutinib maintenance in newly diagnosed non-GCB subtype of DLBCL patients with MYC-high + BCL2-high selected by IHC.

The study will include a Screening Phase, Combination Treatment Phase, Maintenance phase and a Post Treatment Follow-up Phase.

Condition Diffuse Large B-cell Lymphoma(DLBCL)
Treatment Zanubrutinib + R-CHOP
Clinical Study IdentifierNCT05189197
SponsorFudan University
Last Modified on14 March 2022


Yes No Not Sure

Inclusion Criteria

Subject must be 18 years of age or older
No prior treatment for DLBCL
Histologically - confirmed non-GCB subtype
MYC+≥40% and BCL2+≥50% by IHC
Lesions must be measurable. A measurable node lesion must have a longest diameter greater than 1.5 cm. A measurable extra-nodal lesion should have a longest diameter greater than 1.0 cm
Eastern Cooperative Oncology Group performance status grade of 0, 1, or 2
Stage II (not candidates for local X-ray therapy), III, or IV disease by the Ann Arbor Classification
Hematology values must be within the following limits at baseline
Neutrophils ≥ 1 x 109/L, independent of growth factor support within 7 days of initiation of the combination therapy
Platelets ≥ 75x 109/L, independent of growth factor support or transfusion within 7 days of initiation of the combination therapy. (platelets≥ 50 x 109/L, if there is bone marrow involvement.)
Biochemical values must be within the following limits at baseline
Alanine aminotransferase (ALT) ≤3 x upper limit of normal (ULN). Aspartate aminotransferase (AST) ≤3 x ULN
Total bilirubin ≤1.5 x ULN, unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin
Serum creatinine ≤2 x ULN or estimated Glomerular Filtration Rate≥40 mL/min/1.73m2
International normalized ratio (INR) ≤1.5 and activated partial thromboplastin time
(APTT) ≤1.5 x ULN
Able to provide written informed consent, can understand and comply breastfeeding are
ineligible for this study

Exclusion Criteria

Primary mediastinal lymphoma
Central nervous system involvement lymphoma
Histologically transformed lymphoma
Diagnosed or treated for malignancies other than DLBCL
History of stroke or intracranial hemorrhage within 6 months
Major surgery within 4 weeks
Required ongoing treatment with medication that are strong cytochrome P450, family 3
subfamily A (CYP3A) inhibitors or strong/median effect CYP3A inducers
Clinically significant cardiovascular disease such as uncontrolled or symptomatic
arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by
the New York Heart Association Functional Classification, or Echocardiography: Left
ventricular ejection fraction (LVEF) < 50%
Active, clinically significant Electrocardiogram (ECG) abnormalities including second
degree atrioventricular (AV) block Type II, or third-degree AV block or QT interval
corrected for heart rate (QTcF) prolongation, defined as a QTcF > 450 msec
Any uncontrolled active systemic infection requiring intravenous (IV) antibiotics
Known human immunodeficiency virus (HIV) infection, or active hepatitis B or hepatitis
C infection
Any life-threatening illness, medical condition, or organ system dysfunction which, in
the investigator's opinion, could compromise the subject's safety, interfere with the
absorption or metabolism of zanubrutinib capsules, or put the study outcomes at undue
Pregnant or lactating women
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note